Author: Castle Biosciences, Inc.

Posted Date:

May 13, 2026

Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference

Castle Biosciences, Inc.

May 13, 2026
Castle Biosciences’ AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation

Castle Biosciences, Inc.

May 12, 2026
Castle Biosciences Reports First Quarter 2026 Results

Castle Biosciences, Inc.

May 8, 2026
New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett’s Esophagus

Castle Biosciences, Inc.

May 5, 2026
Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month

Castle Biosciences, Inc.

May 5, 2026
Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma’s Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS

Castle Biosciences, Inc.

April 21, 2026
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026

Castle Biosciences, Inc.

April 15, 2026
Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year

Castle Biosciences, Inc.

April 10, 2026
Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026

Castle Biosciences, Inc.

March 27, 2026
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB

Castle Biosciences, Inc.

March 13, 2026